No differences were observed in changes in insulin resistance, β-cell function, HDL, triglyceride, blood pressure, hsCRP and adiponectin (data not presented) between Xiaoke Pill and Glibenclamide treatment arms. This evidence concerns the gene ADIPOQ and Insulin resistance.